touchPODCAST

Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals

touchIN CONVERSATION for touchINFECTIOUS DISEASES

Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings.

The experts

• Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA
• Dr Marc Steben, HPV Global Action and Université de Montréal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchinfectiousdiseasesime.org/in-conversation-improving-hpv-vaccine-uptake/

Looking to the future in the treatment of steroid-refractory chronic GvHD

touchFOCUS for touchONCOLOGY

In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies.

The expert:

• Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA
  

This touchPODCAST is for HCPs outside the UK. 

This activity is funded by an independent medical education grant from Sanofi US.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com

Looking to the future in the treatment of steroid-refractory chronic GvHD

touchFOCUS for touchHAEMATOLOGY

In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies.

The expert:

• Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA
  

This touchPODCAST is for HCPs outside the UK. 

This activity is funded by an independent medical education grant from Sanofi US.

This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchHAEMATOLOGY.com

Updates in BCMA-directed therapies in multiple myeloma from ASH 2024

touchCONGRESS for ONCOLOGY

Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. 

The experts

• Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
• Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA
• Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic

This touchPODCAST is for HCPs outside of the USA and UK.

This activity is funded by an independent medical education grant from GSK. 

This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchoncologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/

Updates in BCMA-directed therapies in multiple myeloma from ASH 2024

touchCONGRESS for touchHAEMATOLOGY

Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. 

The experts

• Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
• Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA
• Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic

This touchPODCAST is for HCPs outside of the USA and UK.

This activity is funded by an independent medical education grant from GSK. 

This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchhaematologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/

RAS mutations and personalized cancer care: Targeting the future

touchEXPERT OPINIONS for touchONCOLOGY

Listen to a medical oncologist, a pancreatic cancer specialist and a lung cancer specialist discuss the role of RAS mutations in solid tumours, notably pancreatic cancer and NSCLC, and how they may be therapeutically targeted to improve patient outcomes.

The experts

• Dr David S Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
• Dr Eileen M O’Reilly, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
• Dr Rebecca S Heist, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

This touchPODCAST is for healthcare professionals outside of the UK.

 

This activity is funded by an independent medical education grant from Revolution Medicines.

 

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

 

For further information visit our website: 

https://touchoncologyime.org/mutations-and-personalized-cancer-care-targeting-the-future/

 

What’s new in primary ITP? Key updates from ASH 2024

touchPANEL DISCUSSION for touchONCOLOGY

Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition.  

The experts

• Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA
• Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK
• Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi.

This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider.

For further information visit our website:
https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#

What’s new in primary ITP? Key updates from ASH 2024

touchPANEL DISCUSSION for touchHAEMATOLOGY

Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition.  

The experts

• Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA
• Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK
• Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi.

This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider.

For further information visit our website:
https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#

Focused insights: Data implications of ADCs in NSCLC treatment

touchFOCUS for touchRESPIRATORY

Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future.

The expert

• Prof. Céline Mascaux, Strasbourg University, Strasbourg, France

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from AstraZeneca.

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: 
www.touchrespiratory.org/ADCs-in-NSCLC

Focused insights: Data implications of ADCs in NSCLC treatment

touchFOCUS for touchONCOLOGY

Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future.

The expert

• Prof. Céline Mascaux, Strasbourg University, Strasbourg, France

This touchPODCAST is for HCPs only

This activity is funded by an independent medical education grant from AstraZeneca.

This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:
www.touchoncology.org/ADCs-in-NSCLC